Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 22, 2026

Alan Greenspan, who steered the Federal Reserve through both boom and crisis, dies at 100

View original at finance.yahoo.com
Alan Greenspan, who steered the Federal Reserve through both boom and crisis, dies at 100 Alan Greenspan, the professional economist who presided over the Federal Reserve during nearly two decades of boom and bust, died on Monday…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Federal Reserve sets policy for the world's largest economy, and other central banks defer to or calibrate their decisions against the Fed's, which exerts enormous sway over asset prices around the world

    60% confidence
  • Greenspan described himself as a reluctant decision-maker, a dynamic solidified by the aftermath of Sept. 11, when the Bush administration called upon his expertise to forge a policy response

    60% confidence
  • Greenspan never felt entirely comfortable being cast as the person who calls the shots; viewed himself as an expert behind the scenes, an implementer of orders rather than the leader

    60% confidence
  • The stock market crisis of 1987 (Black Monday) made Greenspan feel comfortable making critical policy decisions, but he remained ill at ease in the spotlight and described himself as not an extrovert

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com